Millipore Corp. expanded its agreement with Novo Nordisk to provide recombinant human insulin, a key cell culture supplement used to manufacture biologic drugs. Under the terms of the agreement, Millipore will have exclusive worldwide rights to market and sell Novo Nordisk’s recombinant human insulin, branded by Millipore as Incelligent SG and Incelligent AF, for cell culture media applications. Incelligent is an insulin product used in the production of several biologic drugs on the ...